This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rudick, R. Articles by Fischer, J Search for Related Content PubMed Articles by Rudick, R. Articles by Fischer, J Social Bookmarking                         What's this?

Multiple sclerosis progression in a natural history study: Predictive value of cerebrospinal fluid free kappa light chains

Departments of Neurology (Mellen Center for Multiple Sclerosis Treatment and Research)

SV Medendorp

Biostatistics and Epidemiology, Area U-100, Cleveland Clinic Foundation, Cleveland, Ohio 44106, USA

M Namey

Departments of Neurology (Mellen Center for Multiple Sclerosis Treatment and Research)

S Boyle

Neuroscience, Area U-100, Cleveland Clinic Foundation, Cleveland, Ohio 44106, USA

J Fischer

Departments of Neurology (Mellen Center for Multiple Sclerosis Treatment and Research)

Objectives: To determine the relationship between baseline CSF immunologic abnormalities and MS disease progression; To determine progression rates in an untreated, recently-diagnosed MS sample using several validated clinical measures.

Background: CSF immune abnormalities are common in MS but have not been linked to disease progression.

Design Methods: Thirty-six patients with definite (n=28), probable (n=2), or possible (n=6) MS were studied prospectively. Baseline CSF was analyzed for free kappa and lambda light chains, myelin basic protein, IgG synthesis rate, and IgG index. MS patients were entered into the study within 5 years of symptom onset and examined semiannually for as long as 53.4 months (median length offollow up 38.9 months). MS progression was defined as sustained worsening on the following clinical measurement instruments: the Expanded Disability Status Scale (EDSS), the Ambulation Index (AI), the 9 Hole Peg Test (9HT) and the Box and Blocks test (BBT). Kaplan-Meier estimates of disease progression were calculated and the relationship between baseline CSF values and disease progression was determined using Cox proportional hazards regression models.

Results: By 36 months, 33% (95% Cl-10.3, 55.7) of patients had progressed on EDSS and 49.7% (95% Cl=27.7, 71.7) had progressed on at least one of the outcome measures. Patients with CSF free kappa chain levels in the upper quartile had a significantly higher risk of progression on EDSS (Hazard Ratio 3.78; p=0.04) and 9HT (Hazard Ratio 10.77, p=0.04).

Conclusions: In this study, CSF free kappa light chains predicted subsequent physical deterioration in prospectively evaluated MS patients. If this is confirmed by larger studies, then CSF free kappa light chains could serve as a target for intervention in therapeutic trials.

Key Words: multiple sclerosis • cerebrospinal fluid • kappa chains • prognostic epidemiologic study

Multiple Sclerosis, Vol. 1, No. 3, 150-155 (1995)
DOI: 10.1177/135245859500100303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. R. Rinker II, K. Trinkaus, R. T. Naismith, and A. H. Cross Higher IgG index found in African Americans versus Caucasians with multiple sclerosis Neurology, July 3, 2007; 69(1): 68 - 72. [Abstract] [Full Text] [PDF]

				J. R. Rinker II, K. Trinkaus, and A. H. Cross Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology, October 10, 2006; 67(7): 1288 - 1290. [Abstract] [Full Text] [PDF]

				E. J. Thompson Quality versus Quantity: Which Is Better for Cerebrospinal Fluid IgG? Clin. Chem., October 1, 2004; 50(10): 1721 - 1722. [Full Text] [PDF]

				C. Fischer, B. Arneth, J. Koehler, J. Lotz, and K. J. Lackner Kappa Free Light Chains in Cerebrospinal Fluid as Markers of Intrathecal Immunoglobulin Synthesis Clin. Chem., October 1, 2004; 50(10): 1809 - 1813. [Abstract] [Full Text] [PDF]

				G. R. Cutter, M. L. Baier, R. A. Rudick, D. L. Cookfair, J. S. Fischer, J. Petkau, K. Syndulko, B. G. Weinshenker, J. P. Antel, C. Confavreux, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure Brain, May 1, 1999; 122(5): 871 - 882. [Abstract] [Full Text] [PDF]